Molecular glue degraders: Lilly, AbbVie sign billion-dollar deals; BMS leads with three late-stage drugs

Data Compilation
#PharmaFlow

Pipeline Prospector Feb 2025: Bain buys Mitsubishi Tanabe for US$ 3.4 bn; Japan’s Ono gets FDA nod for rare joint tumor drug

Stock Recap
#PipelineProspector

Propafenone Hydrochloride

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

16 API Suppliers, 12 USDMF, 5 CEP/COS, 2 JDMF, 5 EU WC, 2 KDMF, 14 NDC API, 7 Listed Suppliers, $ API Reference Price

INTERMEDIATES

1 Intermediate Suppliers

1 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

103 FDF Dossiers, 53 FDA Orange Book, 30 Europe, 10 Canada, 2 South Africa, 8 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 150MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 225MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE, EXTENDED RELEASE;ORAL - 225MG, CAPSULE, EXTENDED RELEASE;ORAL - 325MG, CAPSULE, EXTENDED RELEASE;ORAL - 425MG

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc, 5 SPI Pharma, 10 DKSH, 7 Faran Shimi Pharmaceutical, 8 Boai NKY Pharmaceuticals Ltd, 5 Gangwal Healthcare, 4 Nanjing Well Pharmaceutical, 4 ACG Worldwide, 6 Actylis, 1 Aeon Procare, 1 Alcedo Pharmachem, 9 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 32 BASF, 11 Corel Pharma Chem, 7 DFE Pharma, 2 Finar, 11 Gangwal Chemicals, 5 Ideal Cures Pvt Ltd, 4 Ingredion Pharma Solutions, 37 Kerry, 4 Kima Chemical, 6 Lonza Capsugel, 15 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nomisma Healthcare, 3 Novo Excipients, 4 Pharmatrans-Sanaq, 7 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 25 Roquette, 14 Seppic, 6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 12 Sigachi Industries, 3 The Dow Chemical Company, 2 Ulanqab Kema New Material, 1 Valens Pharmachem, 4 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

80 Fillers, Diluents & Binders, 51 Coating Systems & Additives, 38 Disintegrants & Superdisintegrants, 32 Thickeners and Stabilizers, 32 Granulation, 32 Direct Compression, 31 Controlled & Modified Release, 29 Solubilizers, 19 Lubricants & Glidants, 17 Film Formers & Plasticizers, 15 Topical, 14 Co-Processed Excipients, 14 Taste Masking, 10 Chewable & Orodispersible Aids, 10 Parenteral, 9 Empty Capsules, 9 Emulsifying Agents, 6 Rheology Modifiers, 6 API Stability Enhancers, 5 Coloring Agents, 4 Vegetarian Capsules, 3 Surfactant & Foaming Agents

DIGITAL CONTENT

13 News #PharmaBuzz

13 News #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 33 Regulatory FDF Prices

MARKET PLACE

7 APIs, 3 FDF Dossiers

REF. STANDARDS & IMPURITIES

2 EDQM, 3 USP, 3 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Registrant Name	Registration No.	Compound	Registration Date	Manufacturer	Manufacturer's Country	Manufacturer's Address
28/03/2025	Axplora	Germany	Abbott Korea Ltd.	20220124-209-J-1222	Propafenone hydrochloride	2022-01-24	PharmaZell GmbH	Germany	Rosenheimer Straße 43 83064 Raubling Germany
28/03/2025	SCI Pharmtech	Taiwan	Aging Life Science Co., Ltd.	20210316-209-J-662	Propafenone hydrochloride	2021-03-16	SCI Pharmtech, Inc	Taiwan	No.61, Ln.309, Haihu N. Rd., Luzhu Dist. Taoyuan City 33856, Taiwan

Propafenone Hydrochloride

Propafenone Hydrochloride

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

16 API Suppliers

12 USDMF

5 CEP/COS

2 JDMF

5 EU WC

2 KDMF

14 NDC API

7 Listed Suppliers

$ API Reference Price

INTERMEDIATES

1 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

103 FDF Dossiers

53 FDA Orange Book

30 Europe

10 Canada

2 South Africa

8 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 150MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 225MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE, EXTENDED RELEASE;ORAL - 225MG

CAPSULE, EXTENDED RELEASE;ORAL - 325MG

CAPSULE, EXTENDED RELEASE;ORAL - 425MG

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc

5 SPI Pharma

10 DKSH

7 Faran Shimi Pharmaceutical

8 Boai NKY Pharmaceuticals Ltd

5 Gangwal Healthcare

4 Nanjing Well Pharmaceutical

4 ACG Worldwide

6 Actylis

1 Aeon Procare

1 Alcedo Pharmachem

9 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

32 BASF

11 Corel Pharma Chem

7 DFE Pharma

2 Finar

11 Gangwal Chemicals

5 Ideal Cures Pvt Ltd

4 Ingredion Pharma Solutions

37 Kerry

4 Kima Chemical

6 Lonza Capsugel

15 Microlex e.U

1 Nanjing Bold Chemical

2 Nomisma Healthcare

3 Novo Excipients

4 Pharmatrans-Sanaq

7 Pluviaendo

4 Prachin Chemical

1 Qianhao Chemical (Hebei) Co., Ltd

2 Qualicaps

25 Roquette

14 Seppic

6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shanghai Welltone Material Technology Co., Ltd

12 Sigachi Industries

3 The Dow Chemical Company

2 Ulanqab Kema New Material

1 Valens Pharmachem

4 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

80 Fillers, Diluents & Binders

51 Coating Systems & Additives

38 Disintegrants & Superdisintegrants

32 Thickeners and Stabilizers

32 Granulation

32 Direct Compression

TABLET;ORAL - 150MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 225MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 300MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons